Laureate  Pharma, Inc. (Princeton, NJ) has entered into a cGMP contract manufacturing  agreement with ARIUS Research, Inc. (Toronto, Canada) for its Trop-2 signal  transduction antibody program. Under the agreement, Laureate will produce  ARIUS’s IgG1 humanized antibody. ARIUS’s Trop-2 antibody program targets a  novel marker that has been linked to aggressive cancers including pancreatic,  colon, breast, and prostate cancer.

News

Laureate Pharma, Inc. (Princeton, NJ) has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc. (Toronto, Canada) for its Trop-2 signal transduction antibody program.